Table 2. Multivariate analysis of a Cox’s hazard model in relation to progression-free survival and overall survival (unweighted original cohort).
| Variables | Progression-free survival | Overall survival | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| Age (yr) | |||||
| ≤55 | Reference | 0.513 | Reference | 0.907 | |
| >55 | 1.095 (0.834–1.439) | 0.980 (0.703–1.367) | |||
| FIGO stage | |||||
| II | Reference | <0.001 | Reference | <0.001 | |
| III–IV | 2.866 (1.862–4.411) | 2.565 (1.551–4.241) | |||
| Residual tumor | |||||
| None | Reference | 0.021 | Reference | 0.055 | |
| <1 cm | 1.486 (1.061–2.083) | 1.506 (0.991–2.288) | |||
| Surgery | |||||
| Non-RLNA | Reference | 0.039 | Reference | 0.017 | |
| RLNA | 0.741 (0.558–0.985) | 0.652 (0.459–0.927) | |||
| Chemotherapy | |||||
| Non-TP | Reference | 0.739 | Reference | 0.055 | |
| TP | 0.942 (0.665–1.336) | 0.679 (0.457–1.008) | |||
| Treatment era | |||||
| <2010 | Reference | 0.151 | Reference | 0.757 | |
| ≥2010 | 1.241 (0.924–1.666) | 1.064 (0.720–1.572) | |||
CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; RLNA, retroperitoneal lymphadenectomy; TP, taxane plus platinum.